Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 8.6%

AnaptysBio, Inc. (NASDAQ:ANAB) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 6,710,000 shares, a growth of 8.6% from the October 31st total of 6,180,000 shares. Currently, 25.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 403,100 shares, the short-interest ratio is currently 16.6 days.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ANAB shares. UBS Group increased their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday. Guggenheim upped their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright decreased their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

Insider Activity

In related news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 in the last quarter. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Ensign Peak Advisors Inc increased its holdings in shares of AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock valued at $1,898,000 after purchasing an additional 32,313 shares during the period. Assenagon Asset Management S.A. grew its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares during the last quarter. Victory Capital Management Inc. increased its stake in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after buying an additional 206,750 shares during the period. Alpha DNA Investment Management LLC purchased a new position in AnaptysBio during the 2nd quarter worth $399,000. Finally, nVerses Capital LLC lifted its stake in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the period.

AnaptysBio Trading Down 2.3 %

Shares of ANAB opened at $24.38 on Tuesday. The company’s 50 day simple moving average is $27.91 and its 200-day simple moving average is $29.74. The firm has a market cap of $741.88 million, a PE ratio of -4.01 and a beta of -0.24. AnaptysBio has a 12-month low of $14.70 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, equities research analysts forecast that AnaptysBio will post -6.02 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.